ClinicalTrials.gg
CompletedNCT06658652Updated Oct 26, 2024

The Effect of Food and Water Volume in Healthy Adult Participants Administered Enlicitide Decanoate (MK-0616) (MK-0616-022)

A Phase 1 interventional study of Enlicitide decanoate in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 10 months ago, and no results have been posted to the registry.
  • Registered 1 year after the study started (first participant enrolled Oct 2023, registered Oct 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Enlicitide decanoate (MK-0616, the study medicine) is in a class of medicines that have been shown to reduce LDL-C. Enlicitide decanoate is different from the other medicines in this class because it is taken as a tablet and not an injection.

The goal of this study is to see what happens to doses of enlicitide decanoate in a person's body over time. During the study, researchers will measure people's blood samples for the amount of enlicitide decanoate when taken with food or on an empty stomach, or when taken with high, medium, and low volumes of water. Researchers also want to learn about the safety of enlicitide decanoate, including how well people tolerate (manage) it.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Has (BMI) ≥18.0 and ≤32.0 kg/m\^2
  • Is medically healthy with no medical history

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has history of gastrointestinal disease which may affect food and drug absorption
  • Has history of cancer ().
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Enlicitide Decanoate Food Effect

    Participants will be administered enlicitide decanoate on Day 1 with or without food.

    Drug: Enlicitide decanoate

  • Experimental
    Enlicitide Decanoate Water Effect

    Participants will be administered enlicitide decanoate on Day 1 with high, medium, and low volumes of water.

    Drug: Enlicitide decanoate

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Enlicitide Decanoate

    Blood samples will be collected to determine the AUC0-Inf of enlicitide decanoate.

    Time frame: Pre-dose and at designated time points up to 1 week postdose

  2. Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hrs) of Enlicitide Decanoate

    Blood samples will be collected to determine the AUC0-24 of enlicitide decanoate.

    Time frame: Pre-dose and at designated time points up to 24 hours postdose

  3. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Enlicitide Decanoate

    Blood samples will be collected to determine the AUC0-last of enlicitide decanoate.

    Time frame: Pre-dose and at designated time points up to 1 week postdose

  4. Maximum Plasma Concentration (Cmax) of Enlicitide Decanoate

    Blood samples will be collected to determine the Cmax of enlicitide decanoate.

    Time frame: Pre-dose and at designated time points up to 1 week postdose

  5. Time to Maximum Plasma Concentration (Tmax) of Enlicitide Decanoate

    Blood samples will be collected to determine the Tmax of enlicitide decanoate.

    Time frame: Pre-dose and at designated time points up to 1 week postdose

  6. Lag Time (tlag) of Enlicitide Decanoate in Plasma

    Tlag is the time from dosing to the first appearance in plasma. Blood samples will be collected to determine the tlag of enlicitide decanoate.

    Time frame: Pre-dose and at designated time points up to 1 week postdose

  7. Apparent Terminal Half-life (t1/2) of Enlicitide Decanoate

    Blood samples will be collected to determine the t1/2 of enlicitide decanoate.

    Time frame: Pre-dose and at designated time points up to 1 week postdose

  8. Apparent Clearance (CL/F) of Enlicitide Decanoate

    Blood samples will be collected to determine the CL/F of enlicitide decanoate.

    Time frame: Pre-dose and at designated time points up to 1 week postdose

  9. Apparent Volume of Distribution During Terminal Phase (Vz/F) of Enlicitide Decanoate

    Blood samples will be collected to determine the Vz/F of enlicitide decanoate.

    Time frame: Pre-dose and at designated time points up to 1 week postdose

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to 14 days postdose

  2. Number of Participants Who Discontinue Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study due to an AE will be reported.

    Time frame: Up to 14 days postdose

07

Study locations

1 site
  • Celerion (Site 0001)
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Dec 2023, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2024
First posted
Oct 26, 2024
StartActual
Oct 24, 2023
Primary completionActual
Dec 26, 2023
CompletionActual
Dec 26, 2023
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06658652
Responsible party
Sponsor
First posted
Oct 26, 2024
Start date
Oct 24, 2023
Primary completion
Dec 26, 2023
Completion
Dec 26, 2023
Last update
Oct 26, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-0616

Start the discussion